Digestive Diseases and Sciences

, Volume 59, Issue 3, pp 614–622 | Cite as

Expression of Ku86 and Presence of Ku86 Antibody as Biomarkers of Hepatitis B Virus Related Hepatocellular Carcinoma

  • Yong Xu
  • Ai-Jun Liu
  • Yuan-Xing Gao
  • Ming-Gen Hu
  • Guo-Dong Zhao
  • Zhi-Ming Zhao
  • Rong Liu
Original Article



Hepatocellular carcinoma (HCC) is a common disease and the third leading cause of cancer-related deaths worldwide. Level of the 82-kDa ATP-dependent DNA helicase II (Ku86) increases in some tumors, but its clinical use as a marker for HCC is rare.


To examine the relationship between increases in Ku86 and the development of hepatitis B virus (HBV)-related HCC to define the relationship between Ku86 and HCC.


Expression of Ku86 in tumor tissue, para-tumor tissue, and normal tissue was examined by immunohistochemistry, and Ku86 antibody titers in patient serum collected pre- and post-operatively were measured by ELISA. Long-term survival of the patients was also monitored.


Ku86 staining in tumors was much stronger than in para-tumor and normal tissues. The expression of Ku86 was related to the tumor size, TNM stage, and tumor differentiation but not to gender, age, Child–Pugh score, tumor number, or α-fetoprotein levels. The long-term survival of patients with low Ku86 expression was longer. Patients with HCC had higher pre-operative Ku86 antibody levels. After surgical intervention, Ku86 antibody levels in patients with HCC declined significantly. Survival analysis showed that double-positive patients had the lowest survival rate, double-negative patients had the highest. Receiver operating characteristic curve analysis showed no significant difference between the AFP and Ku86 antibody. Multivariate analysis showed that Ku86 protein and Ku86 antibodies were independent prognostic factors of overall survival.


Ku86 and Ku86 antibodies are promising tumor markers for early detection and prognosis prediction of HBV-related HCC.


Hepatocellular carcinoma Ku86 Ku86 antibody Prognosis 


Conflict of interest



  1. 1.
    Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics. 2012;6:207–219.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Chen Y, Zhang H, Liao W, et al. FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res. 2013;32:39.PubMedCrossRefGoogle Scholar
  3. 3.
    Takayasu K, Muramatsu Y, Mizuguchi Y, et al. Imaging of early hepatocellular carcinoma and adenomatous hyperplasia (dysplastic nodules) with dynamic ct and a combination of CT and angiography: experience with resected liver specimens. Intervirology. 2004;47:199–208.PubMedCrossRefGoogle Scholar
  4. 4.
    Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol. 2009;193:1053–1060.PubMedCrossRefGoogle Scholar
  5. 5.
    Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989;64:1700–1707.PubMedCrossRefGoogle Scholar
  6. 6.
    Hayashi J, Sakata KI, Someya M, et al. Analysis and results of Ku and XRCC4 expression in hypopharyngeal cancer tissues treated with chemoradiotherapy. Oncol Lett. 2012;4:151–155.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Someya M, Sakata KI, Matsumoto Y, et al. The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer. Br J Cancer. 2011;104:1724–1729.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Kongruttanachok N, Phuangphairoj C, Thongnak A, et al. Replication independent DNA double-strand break retention may prevent genomic instability. Mol Cancer. 2010;9:70.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Tong WM, Cortes U, Hande MP, et al. Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res. 2002;62:6990–6996.PubMedGoogle Scholar
  10. 10.
    Lim JW, Kim H, Kim KH. Expression of Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is related to proliferation of human gastric cancer cells. J Biol Chem. 2002;277:46093–46100.PubMedCrossRefGoogle Scholar
  11. 11.
    Nomura F, Sogawa K, Noda K, et al. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2012;421:837–843.PubMedCrossRefGoogle Scholar
  12. 12.
    Wu F, Wu L, Zheng S, et al. The clinical value of hepatocyte growth factor and its receptor-c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 2006;38:490–497.PubMedCrossRefGoogle Scholar
  13. 13.
    Yang L, Rong W, Xiao T, et al. Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma. Sci China Life Sci. 2013;56:638–646.PubMedCrossRefGoogle Scholar
  14. 14.
    Tameda M, Shiraki K, Sugimoto K, et al. Des-gamma-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma. Cancer Sci. 2013;104:725–731.PubMedCrossRefGoogle Scholar
  15. 15.
    Paul D, Biswas R, Habib SH. Tissue polypeptide specific antigen as a marker used to determine the liver diseases. Kathmandu Univ Med J (KUMJ). 2011;9:24–27.Google Scholar
  16. 16.
    Moeller BJ, Yordy JS, Williams MD, et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res. 2011;17:2035–2043.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lagadec C, Romon R, Tastet C, et al. Ku86 is important for TrkA overexpression-induced breast cancer cell invasion. Proteomics Clin Appl. 2010;4:580–590.PubMedCrossRefGoogle Scholar
  18. 18.
    Suzuki H, Graziano DF, McKolanis J, et al. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res. 2005;11:1521–1526.PubMedCrossRefGoogle Scholar
  19. 19.
    Piura E, Piura B. Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol. 2011;2011:982425.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Caramori G, Adcock IM, Casolari P, et al. Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax. 2011;66:521–527.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Yong Xu
    • 1
  • Ai-Jun Liu
    • 2
  • Yuan-Xing Gao
    • 3
  • Ming-Gen Hu
    • 1
  • Guo-Dong Zhao
    • 1
  • Zhi-Ming Zhao
    • 1
  • Rong Liu
    • 1
  1. 1.Department of Surgical OncologyThe General Hospital of the Chinese People’s Liberation ArmyBeijingChina
  2. 2.Department of General SurgeryThe Central Hospital of ShangluoShangluoChina
  3. 3.The Second Department of General SurgeryThe First Hospital of QiqihaerQiqiharChina

Personalised recommendations